Folic acid supplements together with a medication for high blood pressure called enalapril (Vasotec) reduces the risk of stroke, revealed Chinese researchers.
Researchers studied more than 20,000 adults in China with high blood pressure with no history of stroke or heart attack. 4.5 years after the commencement of the study, 2.7% of those in the enalapril-folic acid group had a stroke, compared to 3.4% in the enalapril group. The results were more pronounced in participants with lower folate levels. However, researchers were unable to see any difference between the two groups when it came to the risk of major hemorrhagic stroke, heart attack, death, or complications.
Folic Acid Supplements Not Beneficial for Heart
The use of folic acid supplements does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period, a new meta-analysis has shown.
Advertisement
"For many populations, achieving adequate levels from diet alone is difficult because of expense or availability. This study seems to support fortification programs where feasible," said the researchers.
The study has been published in the Journal of the American Medical Association (JAMA).
Source: Medindia
Source: Medindia
Study Says Folic Acid Supplements Contribute to Breast Cancer Risk
The offspring of rats that took folic acid supplements before conception, during pregnancy and while breast-feeding have breast cancer rates twice as high as other rats
Advertisement
 Mothers Putting Babies’ Health at Risk by Not Taking Folic Acid Supplements Pre-PregnancyA new study has warned that expecting mothers are putting the health of their babies at risk. | Advertisement
|
Folic Acid Supplements Together With Anti-malarial Drugs Can Reduce Early Infant Mortality
Folic acid supplements together with anti-malarial drugs can reduce early infant mortality, Australian researchers say.
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.